SCHEMBL3834089

SCHEMBL3834089

Cc1ccc(S(=O)(=O)c2cnc3ccccc3c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.66
ALDH1A1 P00352 3/20 0.66
ALPL P05186 3/20 0.66
GAA P10253 2/20 0.57
CYP1A2 P05177 1/20 0.54
RAB9A P51151 3/20 0.52
NPC1 O15118 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
COMT P21964 1/20 0.51
MITF O75030 1/20 0.51
XBP1 P17861 1/20 0.51
PAX8 Q06710 1/20 0.51
KLF5 Q13887 1/20 0.51
LMNA P02545 1/20 0.50
KMT2A Q03164 2/20 0.49
HTT P42858 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30618062 1.00 KDM4E (0.66) KDM4EALDH1A1ALPLGAACYP1A2
SCHEMBL4668553 0.87 ALDH1A1 (0.53) KDM4EALDH1A1ALPLCYP1A2LMNA
SCHEMBL29712704 0.87 ALDH1A1 (0.53) KDM4EALDH1A1ALPLCYP1A2LMNA
SCHEMBL2377244 0.78 ALDH1A1 (0.54) KDM4EALDH1A1ALPLCYP1A2RAB9A
SCHEMBL3053974 0.77 KDM4E (0.56) KDM4EALDH1A1ALPLGAACYP1A2
SCHEMBL2198477 0.77 COMT (0.47) KDM4EALDH1A1ALPLGAASMN1; SMN2
SCHEMBL9587829 0.76 GAA (0.61) KDM4EALDH1A1GAASMN1; SMN2COMT
SCHEMBL30128892 0.76 HTT (0.75) KDM4EALDH1A1ALPLGAARAB9A
SCHEMBL18796178 0.76 HTR2A (0.54) KDM4EALDH1A1ALPLCA12CA1
SCHEMBL8367483 0.76 RAB9A (0.52) KDM4EALDH1A1ALPLCYP1A2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116874419-A Synthesis of antifungal pathogen reagent 湖南大学 2023-10-13 CN disclosed
CN-116874419-A Synthesis of antifungal pathogen reagent 湖南大学 2023-10-13 CN disclosed
US-20090270371-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2009-10-29 US disclosed
EP-1962849-B1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT (HU) 2009-09-30 EP disclosed
CN-101346141-A Quinoline derivatives useful in the treatment of MGLUR5 receptor-mediated disorders RICHTER GEDEON NYRT (HU) 2009-01-14 CN disclosed
EP-1962849-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS Richter Gedeon NYRT (HU) 2008-09-03 EP disclosed
WO-2007072093-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS RICHTER GEDEON NYRT. (HU) 2007-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270371-A1 QUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISORDERS GRM5, GRIK5, GRM1 KDM4E 3941/4885ALDH1A1 2356/4885ALPL 4581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.